Michael B Forster

US Patent:

6495529, Dec 17, 2002

Filed:

Apr 16, 2001

Appl. No.:

09/743052

Inventors:

Anthony Booth - Chester NJ
William T. Sherman - Hendersonville NC
Peter Raven - Forth Worth TX
James L. Caffrey - Burelson TX
Thomas Yorio - Burelson TX
Michael Forster - Fort Worth TX
Patricia Gwirtz - Forth Worth TX

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 31135

US Classification:

514 55, 514648, 514649, 514912

Abstract:

The present invention provides pharmaceutical compositions which include (-)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (-)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (-)-pseudoephedrine to a mammal. The (-)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.

US Patent:

20080242733, Oct 2, 2008

Filed:

Jul 13, 2006

Appl. No.:

11/485928

Inventors:

Anthony Booth - Chester NJ, US
William T. Sherman - Hendersonville NC, US
Peter Raven - Fort Worth TX, US
James L. Caffrey - Burelson TX, US
Thomas Yorio - Burelson TX, US
Michael Forster - Fort Worth TX, US
Patricia Gwirtz - Fort Worth TX, US

International Classification:

A61K 31/137
A61P 11/00

US Classification:

514653

Abstract:

The present invention provides pharmaceutical compositions which include (−)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (−)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (−)-pseudoephedrine to a mammal. The (−)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.